RT @APTAOncologyPT: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy…
Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. #OncologyRehab #ExerciseOncology #CancerRehab #PancreaticCancerAwarenessMonth h
Strength training during ADT for prostate cancer improves sarcopenia, BF%, strength & QOL. No added effect of short-term protein suppl, possibly due to conservative recommendations & small sample size. #exerciseoncology https://t.co/qCJaIlrpEj
A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoing androgen deprivation therapy. Impressive pilot study! https://t.co/UBDMXOvFhQ https://t.co/LZxgGGnWF8
A vigorous intensity resistance #exercise program improves: sarcopenia, body fat, muscular #strength and quality of life in hypogonadal #prostate #cancer patients https://t.co/cP7Bi82cEi #exercise #gymtime #Workout #TrainHard #muscle #lift #GetStrong #Gy
RT @LeighBreen: A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoi…
RT @LeighBreen: A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoi…
RT @LeighBreen: A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoi…
RT @LeighBreen: A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoi…
RT @LeighBreen: A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoi…
RT @LeighBreen: A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoi…
A 12-week resistance training program improved lean mass, body fat %, strength and QOL in prostate cancer patients undergoing androgen deprivation therapy. Impressive pilot study! https://t.co/4RKJ3GPqab